#357 ‒ A new era of longevity science: models of aging, human trials of rapamycin, biological clocks, promising compounds, and lifestyle interventions | Brian Kennedy, Ph.D. | The Peter Attia Drive - Private Subscriber Feed (🔓 for Vijay Khakhria)

In this episode of The Drive, Peter Attia interviews Brian Kennedy, a biologist and aging research expert, about the complexities of aging and longevity research. They discuss Kennedy's move to Singapore to conduct larger clinical aging studies, the surge in longevity research funding around 2017, and different concepts of aging. The conversation covers the limitations of current aging biomarkers, efforts to develop more useful clinical clocks, and compounds like alpha-ketoglutarate and urolithin A. They also explore combining lifestyle factors and pharmacology, emphasizing VO2max, strength training, and GLP-1 agonists, as well as SGLT2 inhibitors, and the potential of rapamycin and other interventions to impact healthspan and lifespan.

Outlines

Part 1: Background, Context

Part 2: Biological Mechanisms, Models

Part 3: Interventions, Clinical Trials

Part 4: Diagnostics, Future Outlook

Sign in to continue reading, translating and more.

Continue

#357 ‒ A new era of longevity science: models of aging, human trials of rapamycin, biological clocks, promising compounds, and lifestyle interventions | Brian Kennedy, Ph.D.

The Peter Attia Drive - Private Subscriber Feed (🔓 for Vijay Khakhria)

Part 1: Background, Context

Introduction to Brian Kennedy and the Buck Institute

Factors Influencing the Acceleration of Longevity Research and the Hallmarks of Aging

Part 2: Biological Mechanisms, Models

Causality of Aging Hallmarks and the Role of mTOR

Entropy, Resilience, and the Linear vs. Exponential Models of Aging

Linear Damage Accumulation vs. Cyclic Volatility and the Gompertz Curve

Speculation on Interventions to Change the Slope of the Aging Line and the Primacy of Epigenetics

Part 3: Interventions, Clinical Trials

The Possibility of Immortality and the Focus on Healthspan

Rapamycin's Effects and Human Clinical Trials

Epigenetic Clocks and Alpha-Ketoglutarate

Urolithin A, Spermidine, and NAD

Sublingual NAD, HRT, and Lifestyle Factors

Part 4: Diagnostics, Future Outlook

Epigenetic Clocks and Clinical Chemistry

Metformin, Rapamycin, GLP-1 Agonists, and SGLT2 Inhibitors

Exercise, Combining Interventions, and AI

Future Directions and Concerns in Longevity Research

#357 ‒ A new era of longevity science: models of aging, human trials of rapamycin, biological clocks, promising compounds, and lifestyle interventions | Brian Kennedy, Ph.D.

The Peter Attia Drive - Private Subscriber Feed (🔓 for Vijay Khakhria)

Part 1: Background, Context

00:10Introduction to Brian Kennedy and the Buck Institute

Introduction to Brian Kennedy and the Buck Institute

04:06Factors Influencing the Acceleration of Longevity Research and the Hallmarks of Aging

Factors Influencing the Acceleration of Longevity Research and the Hallmarks of Aging

Part 2: Biological Mechanisms, Models

13:30Causality of Aging Hallmarks and the Role of mTOR

Causality of Aging Hallmarks and the Role of mTOR

21:58Entropy, Resilience, and the Linear vs. Exponential Models of Aging

Entropy, Resilience, and the Linear vs. Exponential Models of Aging

27:34Linear Damage Accumulation vs. Cyclic Volatility and the Gompertz Curve

Linear Damage Accumulation vs. Cyclic Volatility and the Gompertz Curve

35:21Speculation on Interventions to Change the Slope of the Aging Line and the Primacy of Epigenetics

Speculation on Interventions to Change the Slope of the Aging Line and the Primacy of Epigenetics

Part 3: Interventions, Clinical Trials

42:23The Possibility of Immortality and the Focus on Healthspan

The Possibility of Immortality and the Focus on Healthspan

50:14Rapamycin's Effects and Human Clinical Trials

Rapamycin's Effects and Human Clinical Trials

57:10Epigenetic Clocks and Alpha-Ketoglutarate

Epigenetic Clocks and Alpha-Ketoglutarate

1:04:27Urolithin A, Spermidine, and NAD

Urolithin A, Spermidine, and NAD

1:13:13Sublingual NAD, HRT, and Lifestyle Factors

Sublingual NAD, HRT, and Lifestyle Factors

Part 4: Diagnostics, Future Outlook

1:22:33Epigenetic Clocks and Clinical Chemistry

Epigenetic Clocks and Clinical Chemistry

1:31:24Metformin, Rapamycin, GLP-1 Agonists, and SGLT2 Inhibitors

Metformin, Rapamycin, GLP-1 Agonists, and SGLT2 Inhibitors

1:37:01Exercise, Combining Interventions, and AI

Exercise, Combining Interventions, and AI

1:44:11Future Directions and Concerns in Longevity Research

Future Directions and Concerns in Longevity Research